Elasty® F – Cross-Linked HA Dermal Filler | Non-Lidocaine | 2 × 1ml *SALE*

Elasty® F – Cross-Linked HA Dermal Filler | 2 × 1ml

Product Overview

Elasty® F is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for the correction of superficial to moderate facial wrinkles, refinement of delicate facial contours and subtle enhancement of selected areas.

Formulated with 24mg/ml cross-linked Hyaluronic Acid, Elasty® F features a smooth monophasic gel designed to provide excellent tissue integration, elasticity and natural-looking correction while maintaining normal facial movement and expression.

Elasty® F is manufactured using PNET® (Preserved Natural Entanglement Technology), a patented HA-processing technology designed to preserve the natural entanglement of Hyaluronic Acid chains while producing a cohesive and highly elastic injectable gel.

Its softer characteristics make Elasty® F particularly suited to aesthetic treatments where precision, flexibility and subtle correction are required rather than significant structural projection or deep-volume restoration.

Potential professional treatment objectives include:

• Fine-line correction

• Superficial to moderate wrinkle correction

• Subtle lip enhancement

• Lip contour refinement

• Delicate facial contouring

• Soft tissue correction

• Natural-looking facial rejuvenation

The formulation is designed to integrate smoothly within appropriately selected tissues while providing sufficient elasticity to accommodate facial movement.

Elasty® F is intended strictly for use by appropriately qualified medical or aesthetic professionals with suitable training in dermal filler procedures, facial anatomy and complication management.

Pack Contents

Each pack contains:

• 2 × 1ml pre-filled syringes of Elasty® F

• Cross-Linked Hyaluronic Acid: 24mg/ml

• Sterile needle(s), as supplied by the manufacturer

• Sterile, sealed professional-use packaging

Volume per Syringe: 1ml

Total Product Volume: 2ml

Always check the individual product packaging, supplied needle specifications, manufacturer labelling and current Instructions for Use before administration.

Product CompositionCross-Linked Hyaluronic Acid – 24mg/ml

Elasty® F contains 24mg/ml highly purified cross-linked Hyaluronic Acid.

The supplied product information describes the HA as non-animal stabilised Hyaluronic Acid developed to provide smooth correction and natural tissue integration.

Cross-linking increases the persistence and mechanical stability of Hyaluronic Acid compared with non-cross-linked HA formulations, allowing the gel to provide physical correction within appropriately selected tissues.

Within Elasty® F, the HA gel is designed to support:

• Wrinkle correction

• Subtle volume enhancement

• Tissue hydration

• Contour refinement

• Natural-looking correction

• Smooth tissue integration

Its characteristics are intended for more delicate correction rather than the substantial projection associated with firmer structural dermal fillers.

PNET® – Preserved Natural Entanglement Technology

Elasty® F is manufactured using PNET® – Preserved Natural Entanglement Technology.

According to the supplied product information, PNET® is a patented manufacturing process designed to preserve the natural structure and entanglement of Hyaluronic Acid while reducing unnecessary chemical modification.

The resulting HA gel is designed to provide a balance of:

• Elasticity

• Cohesion

• Durability

• Smooth injectability

• Mouldability

• Tissue integration

These characteristics are particularly important in areas where the filler needs to accommodate normal facial expression and movement while maintaining the intended aesthetic correction.

High-Elasticity Monophasic HA Gel

Elasty® F features a monophasic Hyaluronic Acid gel structure.

A cohesive monophasic formulation is designed to provide smooth and consistent gel behaviour during professional administration and following appropriate placement.

The supplied product information describes Elasty® F as offering:

• High elasticity

• Excellent cohesion

• Smooth injection characteristics

• Good mouldability

• Natural tissue integration

• Durable aesthetic correction

The combination of these characteristics makes Elasty® F particularly suited to treatment objectives requiring subtle, controlled correction.

Fine-Line & Wrinkle Correction

Elasty® F is positioned primarily for superficial to moderate facial correction.

Its softer gel characteristics make it suitable for professional treatment planning where the objective is to soften appropriate lines while maintaining natural movement and avoiding excessive volume.

Potential treatment objectives include:

• Softening fine facial lines

• Improving selected superficial wrinkles

• Correcting appropriate moderate wrinkles

• Refining lip contour

• Providing subtle lip volume

• Improving delicate facial contours

Product selection should always be based on the patient's anatomy, tissue characteristics, treatment area and desired aesthetic outcome.

Subtle Lip Enhancement

Elasty® F may be considered for appropriately selected lip treatments where the objective is subtle enhancement rather than substantial projection or volume.

Depending upon the manufacturer's authorised indications and professional assessment, treatment objectives may include:

• Lip contour refinement

• Subtle volume enhancement

• Improvement of selected perioral lines

• Greater lip definition

• Correction of appropriate asymmetry

• Natural-looking lip rejuvenation

The softer, elastic gel characteristics may be particularly useful where maintaining natural lip movement and softness is an important treatment objective.

Lip treatment should always be individually planned according to anatomy, existing proportions and patient expectations.

Key Benefits

• Professional cross-linked HA dermal filler

• 24mg/ml Hyaluronic Acid

• 2 × 1ml pre-filled syringes

• 2ml total pack volume

• Manufactured using PNET® technology

• Smooth monophasic gel formulation

• High elasticity

• Excellent cohesion

• Designed for natural tissue integration

• Good product mouldability

• Supports superficial to moderate wrinkle correction

• Suitable for delicate facial correction where indicated

• Supports subtle lip enhancement

• Supports lip contour refinement

• Designed to maintain natural facial movement

• Provides immediate physical correction following appropriate placement

• Designed for natural-looking results

• Suitable for professional facial-rejuvenation protocols

• Intended strictly for appropriately qualified professional use

Common Treatment Areas

The supplied product information identifies potential treatment areas including:

• Fine perioral lines

• Lips

• Crow's feet

• Forehead lines

• Glabellar region

• Nasolabial folds

• Marionette region

Not every treatment area will be appropriate for every patient or every filler formulation.

Areas including the glabella and periocular region require particularly careful assessment because of their vascular anatomy and associated complication risks.

Treatment-area suitability must therefore always be determined according to:

• Manufacturer-authorised indications

• Patient anatomy

• Vascular anatomy

• Tissue thickness

• Degree of correction required

• Previous treatments

• Practitioner competence

• Individual treatment objectives

Always follow the manufacturer's current Instructions for Use regarding authorised indications, treatment depth, administration technique, product volume and placement.

Elasty® F – Product Positioning

Within a dermal filler portfolio, Elasty® F is positioned towards finer and more subtle aesthetic correction.

Its softer characteristics make it more appropriate where flexibility and natural integration are required rather than substantial structural support.

Elasty® F

Primarily positioned for:

• Fine lines

• Superficial to moderate wrinkles

• Delicate correction

• Lip contour

• Subtle lip enhancement

• Natural-looking refinement

Firmer Structural Fillers

Firmer HA formulations are generally selected where treatment objectives require greater:

• Projection

• Structural support

• Deep-volume restoration

• Contour definition

• Lifting capacity

Product selection should always be based on rheological characteristics, authorised indications and individual patient assessment rather than HA concentration alone.

Elasty® F vs Skin Boosters

Elasty® F should also be differentiated from non-cross-linked Hyaluronic Acid skin boosters.

HA Skin Boosters

These products primarily focus on:

• Hydration

• Moisture retention

• Skin texture

• Elasticity

• General skin-quality improvement

Elasty® F

As a cross-linked dermal filler, Elasty® F is designed to provide:

• Physical wrinkle correction

• Subtle volume

• Contour refinement

• Tissue support

• Lip enhancement where appropriate

Although Hyaluronic Acid itself attracts water, Elasty® F should not be positioned primarily as a hydrating skin booster.

Recommended Treatment Approach

Elasty® F is generally administered as an individually planned dermal filler treatment following professional assessment.

The supplied information describes a typical approach as:

• Initial Treatment: Single treatment session

• Review: Approximately 2 weeks following treatment where clinically indicated

• Maintenance: Approximately every 9–12 months depending upon treatment area and individual patient factors

These intervals should not be interpreted as a universal protocol or guarantee of treatment duration.

The appropriate treatment plan should be determined according to:

• Patient anatomy

• Treatment area

• Degree of correction required

• Tissue characteristics

• Previous filler treatments

• Product persistence

• Clinical response

• Individual aesthetic objectives

Additional correction should only be considered following appropriate professional reassessment.

Professional Treatment Considerations

Elasty® F should only be administered by appropriately qualified and trained medical or aesthetic professionals with suitable competence in dermal filler procedures.

Treatment planning should include:

• Comprehensive patient consultation

• Full medical history

• Detailed facial assessment

• Assessment of tissue characteristics

• Assessment of facial proportions

• Evaluation of vascular anatomy

• Review of previous filler treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential complications

• Appropriate documented informed consent

The appropriate treatment depth, injection technique, volume and distribution should be determined according to the patient's anatomy, treatment area and manufacturer's current Instructions for Use.

A generic injection protocol should not be applied to every patient or anatomical area.

Results & Longevity

Elasty® F provides an immediate physical correction following appropriate placement.

Depending upon the treatment objective, patients may notice:

• Smoother-looking wrinkles

• Improved facial contours

• Improved lip definition

• Subtle volume enhancement

• Improved symmetry

• Natural-looking facial refinement

Initial swelling following treatment may temporarily influence the early appearance of the treated area.

The final aesthetic outcome becomes clearer as treatment-related swelling subsides and the filler settles within the tissue.

The supplied product information describes a typical clinical longevity of approximately:

9–12 months

This should be considered an approximate range rather than a guaranteed duration.

Individual longevity varies according to:

• Treatment area

• Product volume

• Injection technique

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle

• Tissue characteristics

• Individual biological response

Areas with greater movement may demonstrate different persistence from less mobile treatment areas.

Maintenance treatment may subsequently be considered following professional reassessment.

Natural Facial Movement

A key consideration when treating more mobile facial areas is the ability of a filler to integrate with surrounding tissue while accommodating normal movement.

Elasty® F's high-elasticity, cohesive gel characteristics are designed to support natural-looking correction while maintaining facial expression.

This may be particularly relevant where subtle enhancement is preferred over significant structural alteration.

Treatment outcomes remain highly dependent upon:

• Correct patient selection

• Appropriate product selection

• Treatment depth

• Product volume

• Practitioner technique

• Individual anatomy

Storage & Handling

Elasty® F should be stored and handled according to the manufacturer's current Instructions for Use and the information supplied with the original product.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect the product from inappropriate environmental exposure.

• Inspect each syringe and the outer packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Maintain appropriate aseptic handling procedures.

• Do not use if sterile packaging is damaged.

• Do not use if a syringe appears compromised.

• Do not use after the stated expiry date.

Each syringe is intended for single use according to the manufacturer's Instructions for Use.

Important Information

Elasty® F is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Vascular anatomy

• Dermal filler administration

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Vascular compromise recognition

• Emergency management

• Dermal filler complication management

Patient Assessment

Treatment should only proceed following:

• Full patient consultation

• Comprehensive medical history

• Facial assessment

• Examination of the proposed treatment area

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Contraindications & Precautions

The information supplied does not provide a complete manufacturer-defined contraindication list.

Practitioners should therefore consult the current Elasty® F Instructions for Use rather than relying upon a generic dermal filler contraindication list.

Treatment should not proceed where product sterility, integrity, authenticity or traceability cannot be established.

Potential Treatment Reactions

Temporary effects associated with injectable dermal filler treatment may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Discomfort

• Localised firmness

• Temporary contour irregularity

The precise adverse-event profile should be confirmed from the manufacturer's current Instructions for Use.

Serious Dermal Filler Complications

Injectable dermal filler procedures can result in more serious complications.

These may include infection, inflammatory reactions and vascular complications.

Inadvertent intravascular injection can result in serious tissue injury and, in certain facial regions, potentially severe complications.

Practitioners must therefore have appropriate knowledge of facial vascular anatomy and be competent in recognising and managing filler-related complications.

Particular caution is required when treating anatomically higher-risk regions.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent assessment.

Always consult the manufacturer's current Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, administration and potential adverse events.

For appropriately qualified professional use only.